Bank of New York Mellon’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $513K | Buy |
391,675
+368,462
| +1,587% | +$509K | ﹤0.01% | 3740 |
|
|
2026
Q1 | $36.7K | Hold |
23,213
| – | – | ﹤0.01% | 4155 |
|
|
2025
Q4 | $38.8K | Sell |
23,213
-7,921
| -25% | -$13.7K | ﹤0.01% | 4150 |
|
|
2025
Q3 | $52.6K | Buy |
31,134
+13,339
| +75% | +$15.8K | ﹤0.01% | 4128 |
|
|
2025
Q2 | $16.1K | Sell |
17,795
-320,032
| -95% | -$190K | ﹤0.01% | 4120 |
|
|
2025
Q1 | $153K | Hold |
337,827
| – | – | ﹤0.01% | 3946 |
|
|
2024
Q4 | $170K | Buy |
337,827
+110
| +0% | +$81 | ﹤0.01% | 3983 |
|
|
2024
Q3 | $306K | Sell |
337,717
-98,241
| -23% | -$91.1K | ﹤0.01% | 3754 |
|
|
2024
Q2 | $435K | Buy |
435,958
+114,762
| +36% | +$127K | ﹤0.01% | 3654 |
|
|
2024
Q1 | $475K | Sell |
321,196
-36,940
| -10% | -$41.9K | ﹤0.01% | 3557 |
|
|
2023
Q4 | $390K | Buy |
358,136
+1,275
| +0.4% | +$1.4K | ﹤0.01% | 3691 |
|
|
2023
Q3 | $421K | Hold |
356,861
| – | – | ﹤0.01% | 3644 |
|
|
2023
Q2 | $503K | Buy |
356,861
+286,033
| +404% | +$395K | ﹤0.01% | 3592 |
|
|
2023
Q1 | $106K | Hold |
70,828
| – | – | ﹤0.01% | 4067 |
|
|
2022
Q4 | $82.9K | Buy |
70,828
+1
| +0% | +$1 | ﹤0.01% | 4152 |
|
|
2022
Q3 | $80K | Hold |
70,827
| – | – | ﹤0.01% | 4240 |
|
|
2022
Q2 | $112K | Sell |
70,827
-340,068
| -83% | -$448K | ﹤0.01% | 4202 |
|
|
2022
Q1 | $633K | Sell |
410,895
-10,349
| -2% | -$16.1K | ﹤0.01% | 3575 |
|
|
2021
Q4 | $1.03M | Sell |
421,244
-3,765
| -0.9% | -$8.81K | ﹤0.01% | 3371 |
|
|
2021
Q3 | $1.07M | Buy |
425,009
+43,794
| +11% | +$112K | ﹤0.01% | 3354 |
|
|
2021
Q2 | $1.09M | Buy |
381,215
+308,316
| +423% | +$798K | ﹤0.01% | 3358 |
|
|
2021
Q1 | $171K | Sell |
72,899
-8,926
| -11% | -$21.4K | ﹤0.01% | 4095 |
|
|
2020
Q4 | $144K | Buy |
81,825
+2,940
| +4% | +$4.11K | ﹤0.01% | 4033 |
|
|
2020
Q3 | $74K | Hold |
78,885
| – | – | ﹤0.01% | 3983 |
|
|
2020
Q2 | $69K | Sell |
78,885
-331,600
| -81% | -$292K | ﹤0.01% | 3938 |
|
|
2020
Q1 | $340K | Sell |
410,485
-85,292
| -17% | -$84.9K | ﹤0.01% | 3549 |
|
|
2019
Q4 | $441K | Buy |
495,777
+40,054
| +9% | +$33.4K | ﹤0.01% | 3649 |
|
|
2019
Q3 | $447K | Buy |
455,723
+46,819
| +11% | +$48.5K | ﹤0.01% | 3593 |
|
|
2019
Q2 | $449K | Sell |
408,904
-61,374
| -13% | -$70.7K | ﹤0.01% | 3653 |
|
|
2019
Q1 | $616K | Buy |
470,278
+61,397
| +15% | +$76.4K | ﹤0.01% | 3447 |
|
|
2018
Q4 | $373K | Sell |
408,881
-465,232
| -53% | -$713K | ﹤0.01% | 3621 |
|
|
2018
Q3 | $1.8M | Buy |
874,113
+23,088
| +3% | +$48.5K | ﹤0.01% | 2902 |
|
|
2018
Q2 | $1.53M | Buy |
851,025
+38,119
| +5% | +$76.7K | ﹤0.01% | 3004 |
|
|
2018
Q1 | $1.91M | Buy |
812,906
+60,386
| +8% | +$142K | ﹤0.01% | 2831 |
|
|
2017
Q4 | $1.42M | Buy |
752,520
+225,597
| +43% | +$493K | ﹤0.01% | 3041 |
|
|
2017
Q3 | $1.31M | Sell |
526,923
-15,840
| -3% | -$39.3K | ﹤0.01% | 3079 |
|
|
2017
Q2 | $1.5M | Buy |
542,763
+34,093
| +7% | +$95.2K | ﹤0.01% | 3013 |
|
|
2017
Q1 | $1.53M | Buy |
508,670
+75,660
| +17% | +$215K | ﹤0.01% | 3013 |
|
|
2016
Q4 | $1.37M | Buy |
433,010
+139,987
| +48% | +$430K | ﹤0.01% | 3087 |
|
|
2016
Q3 | $999K | Buy |
293,023
+17,906
| +7% | +$49.5K | ﹤0.01% | 3177 |
|
|
2016
Q2 | $628K | Buy |
275,117
+35,637
| +15% | +$87.4K | ﹤0.01% | 3417 |
|
|
2016
Q1 | $601K | Sell |
239,480
-28,465
| -11% | -$63.5K | ﹤0.01% | 3347 |
|
|
2015
Q4 | $887K | Buy |
267,945
+19,040
| +8% | +$56.9K | ﹤0.01% | 3244 |
|
|
2015
Q3 | $603K | Sell |
248,905
-48,220
| -16% | -$125K | ﹤0.01% | 3491 |
|
|
2015
Q2 | $871K | Buy |
297,125
+45,396
| +18% | +$176K | ﹤0.01% | 3417 |
|
|
2015
Q1 | $1.01M | Sell |
251,729
-14,042
| -5% | -$48.6K | ﹤0.01% | 3302 |
|
|
2014
Q4 | $800K | Buy |
265,771
+37,452
| +16% | +$101K | ﹤0.01% | 3424 |
|
|
2014
Q3 | $579K | Buy |
228,319
+2,018
| +0.9% | +$4.86K | ﹤0.01% | 3568 |
|
|
2014
Q2 | $557K | Buy |
226,301
+21,693
| +11% | +$49K | ﹤0.01% | 3576 |
|
|
2014
Q1 | $543K | Sell |
204,608
-1,982
| -1% | -$5.84K | ﹤0.01% | 3563 |
|
|
2013
Q4 | $600K | Buy |
206,590
+7,711
| +4% | +$23.3K | ﹤0.01% | 3511 |
|
|
2013
Q3 | $610K | Sell |
198,879
-800
| -0.4% | -$2.53K | ﹤0.01% | 3447 |
|
|
2013
Q2 | $638K | Buy |
+199,679
| New | +$640K | ﹤0.01% | 3404 |
|
Other funds holding LCTX
DC
RCWM
FLPIM
N
WJWM
Bank of New York Mellon's LCTX Position: Q2 2026 in Review
Bank of New York Mellon increased its Lineage Cell Therapeutics (LCTX) stake by 1,587% in Q2 2026, buying an estimated $509K and bringing the position to 391,675 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #3740.
Bank of New York Mellon first reported a position in LCTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.91M in Q1 2018. 66 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Bank of New York Mellon held 391,675 shares of Lineage Cell Therapeutics worth $513K as of Q2 2026.
- Bank of New York Mellon bought 368,462 Lineage Cell Therapeutics shares in Q2 2026, an estimated $509K.
- Lineage Cell Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3740 holding.
- Bank of New York Mellon first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Lineage Cell Therapeutics position peaked at $1.91M in Q1 2018.
- 66 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.